By Kelly Cloonan
Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer.
The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months.
The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma.
The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said.
Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 23, 2025 11:25 ET (15:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.